• Consensus Rating: Hold
  • Consensus Price Target: $26.00
  • Forecasted Upside: 82.07%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$14.28
▼ -0.18 (-1.24%)

This chart shows the closing price for QTRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Quanterix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for QTRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for QTRX

Analyst Price Target is $26.00
▲ +82.07% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Quanterix in the last 3 months. The average price target is $26.00, with a high forecast of $60.00 and a low forecast of $12.00. The average price target represents a 82.07% upside from the last price of $14.28.

This chart shows the closing price for QTRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 7 investment analysts is to hold stock in Quanterix. This rating has held steady since May 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/29/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
12/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/27/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2022The Goldman Sachs GroupLower TargetNeutral$15.00 ➝ $13.00Low
11/9/2022SVB LeerinkBoost TargetMarket Perform$12.00 ➝ $15.00Low
8/16/2022Canaccord Genuity GroupDowngradeBuy ➝ HoldLow
8/15/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$40.00 ➝ $12.00Low
8/10/2022The Goldman Sachs GroupLower TargetNeutral$25.00 ➝ $15.00Low
8/9/2022CowenDowngradeOutperform ➝ Market PerformLow
8/9/2022CowenDowngradeOutperform ➝ Market Perform$38.00 ➝ $18.00Low
8/9/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$35.00 ➝ $15.00Low
7/14/2022The Goldman Sachs GroupLower TargetNeutral$30.00 ➝ $25.00Low
5/11/2022CowenLower Target$60.00 ➝ $38.00High
5/11/2022CowenLower Target$60.00 ➝ $38.00High
4/13/2022The Goldman Sachs GroupLower TargetNeutral$40.00 ➝ $35.00High
3/2/2022JPMorgan Chase & Co.Lower TargetOverweight$85.00 ➝ $60.00Medium
3/2/2022SVB LeerinkLower TargetOutperform$70.00 ➝ $50.00Medium
3/2/2022The Goldman Sachs GroupUpgradeSell ➝ Neutral$40.00Medium
6/10/2021SVB LeerinkReiterated RatingBuyHigh
6/4/2021The Goldman Sachs GroupInitiated CoverageSell$53.00High
5/6/2021SVB LeerinkLower TargetOutperform$85.00 ➝ $70.00Low
3/3/2021SVB LeerinkBoost TargetOutperform$75.00 ➝ $85.00High
1/27/2021SVB LeerinkBoost TargetOutperform$50.00 ➝ $75.00High
11/6/2020SVB LeerinkBoost TargetOutperform$48.00 ➝ $50.00High
10/19/2020SVB LeerinkBoost TargetOutperform$37.00 ➝ $48.00Low
8/5/2020JPMorgan Chase & Co.Boost TargetOverweight$30.00 ➝ $40.00High
8/5/2020SVB LeerinkBoost TargetOutperform$35.00 ➝ $37.00High
8/7/2019BTIG ResearchSet TargetBuy$35.00High
5/13/2018BTIG ResearchReiterated RatingBuy$26.00Medium
(Data available from 1/28/2018 forward)

News Sentiment Rating

0.76 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/1/2022
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/31/2022
  • 4 very positive mentions
  • 18 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
8/30/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/29/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/29/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/28/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2022
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2023

Current Sentiment

  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Quanterix logo
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Read More

Today's Range

Now: $14.28
Low: $14.04
High: $14.51

50 Day Range

MA: $13.23
Low: $11.75
High: $14.74

52 Week Range

Now: $14.28
Low: $6.31
High: $35.98

Volume

122,689 shs

Average Volume

302,508 shs

Market Capitalization

$529.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Quanterix?

The following Wall Street analysts have issued reports on Quanterix in the last twelve months: Canaccord Genuity Group Inc., Cowen Inc, Cowen Inc., JPMorgan Chase & Co., SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for QTRX.

What is the current price target for Quanterix?

6 Wall Street analysts have set twelve-month price targets for Quanterix in the last year. Their average twelve-month price target is $26.00, suggesting a possible upside of 82.1%. JPMorgan Chase & Co. has the highest price target set, predicting QTRX will reach $60.00 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of $12.00 for Quanterix in the next year.
View the latest price targets for QTRX.

What is the current consensus analyst rating for Quanterix?

Quanterix currently has 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in QTRX, but not buy more shares or sell existing shares.
View the latest ratings for QTRX.

What other companies compete with Quanterix?

How do I contact Quanterix's investor relations team?

Quanterix's physical mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company's listed phone number is (617) 301-9400 and its investor relations email address is [email protected] The official website for Quanterix is www.quanterix.com. Learn More about contacing Quanterix investor relations.